A trial with IgY chicken antibodies to eradicate faecal carriage of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta-lactamases

Figures & data

Fig. 1.  Study flow chart of the screening and randomisation process, treatment, and follow-up for the participants in the study.

Fig. 2.  Flow chart of the number of participants who did not complete the study until randomisation. LFU: lost to follow-up; SC: failure to meet with the study criteria; HTTP: high threshold to participate.

Table 1 ESBL carriage: age, sex, strains, and the time interval between samples from the first and second positive test at the screening test of the enrolment group

All patients	Carriers with detectable ESBL n=30	Carriers with undetectable ESBL n=58	p
Age median (IQR)	63.5 (17)	66.5 (20)	NS^a
Sex (M/F)	10/20	24/34	NS^b
Previous carriers of
E. coli	27	46
K. pneumoniae	2	12
Both strains	1
Median time (in months) interval between first and second samples (IQR)	7 (10)	12.5 (11)	0.029^a
Outbreak patients (K. pneumoniae)	n=1	n=7
Age median (IQR)	64	70 (3.5)
Sex (M/F)	1/0	5/2
Median time (in months) interval between first and second samples (IQR)	40	64 (11.4)

NS, not significant. ^aPaired t-test; ^bchi-square test.